Mescaline, the Nervous System and Feeling Safe: What We Know & What We Don’t

This article is intended for general information and discussion of current research. It is not medical advice.

The nervous system has become a common way of explaining experiences in discussions around psychedelics and retreats. Difficult emotions may be described as nervous system dysregulation, physical sensations as stored trauma, and powerful experiences as evidence that something is being released or healed. Some of this language draws loosely on genuine areas of research, but it is often used with far more certainty than the evidence allows.

There is useful research into mescaline, psychedelic experiences, neuroplasticity and the influence of context. There are also significant gaps in what we know. My experience working with Huachuma allows me to speak to what I have observed in people and in ceremony, but it does not provide a complete explanation of what is happening in someone's brain or nervous system. Keeping those two forms of knowledge separate is important.

What We Actually Know About Mescaline

Mescaline is the primary psychoactive alkaloid found in Huachuma, also known as San Pedro. It is a classic serotonergic psychedelic, and its acute psychedelic effects appear to be mediated primarily through serotonin 5-HT2A receptors (Klaiber et al., 2024; Shaw et al., 2026).

Modern controlled research is still relatively limited. In a 2024 double-blind, placebo-controlled study involving 16 healthy participants, mescaline produced dose-dependent changes in subjective experience. The study also recorded temporary increases in heart rate and blood pressure, with the duration of subjective effects increasing at higher doses (Klaiber et al., 2024).

That tells us something useful about mescaline's acute effects, but it does not establish that mescaline treats psychological conditions or “heals the nervous system.” A 2026 clinical review found that controlled trials in patient populations remain scarce and that most modern safety data come from screened healthy volunteers. The authors also note continuing uncertainty around psychological risks, longer-term safety and use in people with cardiovascular, metabolic or psychiatric conditions (Tabaac et al., 2026).

A separate 2026 systematic review reached a similarly cautious conclusion. Although previous studies have reported potential benefits across several areas, the available mescaline literature remains limited and highly variable in quality, making firm conclusions difficult to draw (Shaw et al., 2026). For that reason, I would not describe Huachuma as something that has been scientifically shown to heal or regulate the nervous system.

Why Context and Feeling Safe Still Matter

Being cautious about neurological claims does not make the environment unimportant. Psychedelic research commonly refers to set and setting: factors connected to the person taking the psychedelic and the physical, social and psychological environment around the experience.

A 2025 systematic review examining clinical psychedelic studies found that preparation, participant selection, the presence of monitors or therapists, environmental management, and post-session support were recurring parts of how psychedelic interventions were structured (Estric et al., 2025). At the same time, researchers have been careful not to overstate what this proves. A broader review of setting research found considerable agreement that context matters, while also noting that specific elements of setting have not been tested rigorously enough to say exactly which factors affect outcomes, for whom, or through what mechanisms (Golden et al., 2022).

From years of working with people, I can see that a person's expectations, current circumstances, the people around them, and how secure they feel in the environment can influence how they respond to an unfamiliar experience. That is an observation about people, not a claim about a specific neurological mechanism.

Feeling safe also does not mean feeling comfortable throughout ceremony. Fear, sadness, confusion, physical discomfort or difficult memories can still arise. The practical value of a well-held environment is that someone knows where they are, who is with them, how to ask for support, and that someone is paying attention if they need help. I do not think we need to describe that as nervous system healing for it to matter.

Difficult Experiences Are Not Proof of “Trauma Release”

One of the areas where the language around psychedelics can become particularly vague is the idea that strong emotions or physical sensations automatically represent trauma being released from the body. I would not make that assumption.

People can experience shaking, nausea, changes in breathing, tension, fear, crying, anger or many other physical and emotional responses during a psychedelic experience. Those experiences may be important to the person, but observing them does not tell us exactly what they represent.

The same applies when memories come up. Somebody may connect an emotion or physical sensation with something that happened earlier in their life, and that connection may remain important afterwards. Another person may understand the same experience very differently once they have had time to reflect. Something can matter without needing an immediate explanation. This deserves particular care during ceremony because people can be highly open to suggestion. Telling somebody that they are “releasing stored trauma” may influence how they understand what is happening before they have had the chance to reach their own conclusions.

What Neuroplasticity Research Can and Cannot Tell Us

Neuroplasticity has also become common language in psychedelic discussions, sometimes reduced to claims that psychedelics “rewire the brain.”

There is legitimate research behind the broader subject. A 2025 review examining 70 preclinical and clinical studies found strong preclinical evidence that psychedelics can influence biological processes associated with neuroplasticity. Human evidence is developing, but it remains harder to measure directly and to connect those biological changes with specific psychological outcomes (Weiss et al., 2025).

Evidence that psychedelics influence mechanisms associated with neural plasticity does not mean we can look at an individual Huachuma experience and conclude that the person's brain has been “rewired,” or that neuroplasticity explains whatever changes they notice afterwards. It is an interesting and developing area of research, but it should stay within the limits of what has actually been demonstrated.

What Experience Can Tell Us & What It Cannot

There are things I can speak about with more confidence from years of working with people. Preparation matters. Who is facilitating and how they respond matters. Group dynamics matter. Expectations matter. The surroundings matter. What is happening in somebody's life when they arrive can also affect how they engage with the experience.

None of these things determines what will happen. I have seen people respond very differently under apparently similar circumstances. One person may spend much of a ceremony reflecting quietly while another becomes highly emotional. Someone may arrive expecting a major experience and find the day relatively subtle, while another may encounter something they had not anticipated. That variation is one reason I am reluctant to explain Huachuma through a single mechanism.

The same applies when somebody experiences something difficult. There can be a temptation to give them an explanation: their nervous system is regulating, trauma is releasing, their body is letting go, or the medicine is showing them something. I do not claim to have all the answers. My role is to know enough about the person, the medicine and the circumstances to support what is happening while remaining clear about the limits of what I know.

Sometimes somebody needs reassurance or practical support. Sometimes they want to talk through what they are experiencing, and sometimes giving them time without immediately attaching an interpretation is more useful. What feels completely clear during ceremony may also look different the following morning or several weeks later.

Where This Leaves Us

There is research explaining parts of mescaline's acute pharmacology, growing research into psychedelics and neuroplasticity, and an expanding scientific discussion around the role of context. There are also substantial gaps, particularly when it comes to mescaline's longer-term effects and its potential therapeutic use in clinical populations.

Practical experience contributes something different. Years of working with people can teach us about preparation, communication, group dynamics, support, and how people respond differently to similar circumstances. It does not turn those observations into neuroscience.

Both deserve to be taken seriously without confusing one for the other. There are things science can currently tell us about mescaline, things experience can teach us about working with people, and things we still do not know. We do not need a neurological or spiritual explanation for every experience in order to take it seriously.

References

Estric, C., Duron, T., Kabani, S., & Lopez-Castroman, J. (2025). Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review. Journal of Psychopharmacology, 39(9), 910–929. DOI: 10.1177/02698811251338214.

Golden, T. L., Magsamen, S., Sandu, C. C., Lin, S., Roebuck, G. M., Shi, K. M., & Barrett, F. S. (2022). Effects of setting on psychedelic experiences, therapies, and outcomes: A rapid scoping review of the literature. Current Topics in Behavioral Neurosciences, 56, 35–70. DOI: 10.1007/7854_2021_298.

Klaiber, A., Schmid, Y., Becker, A. M., Straumann, I., Erne, L., Jelusic, A., Thomann, J., Luethi, D., & Liechti, M. E. (2024). Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects. Translational Psychiatry, 14, 395. DOI: 10.1038/s41398-024-03116-2.

Shaw, J., Yong, A., Lee, J., Cheng, J., Andricioaei, A., Wang, J.-Y., Zisman-Ilani, Y., & Bota, R. (2026). The ethnopharmacological use of mescaline for psychiatric disorders: A systematic review. International Journal of Molecular Sciences, 27(7), 3081. DOI: 10.3390/ijms27073081.

Tabaac, B. J., Shinozuka, K., Fadel, M., Jones, G., Worchel, J., & Muir, O. S. (2026). Psychedelic therapy: A primer for primary care clinicians—Mescaline. American Journal of Therapeutics, 33(4), e318–e323. DOI: 10.1097/MJT.0000000000002160.

Weiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025). Psychedelic-induced neural plasticity: A comprehensive review and a discussion of clinical implications. Brain Sciences, 15(2), 117. DOI: 10.3390/brainsci15020117.